Asset icon - trade crypto, stocks, and gold on Pluang
Trade on Pluang
One platform for all markets
Download
Investment
Features
FeesSafety
Academy
More
Pluang+

Siren ETF Trust to liquidate LEAD and BLCN ETFs by July 21, 2026

Company Fundamentals
01 Jul 2026
PRNewsWire
View Source
Bearish
pluang ai news

Siren ETF Trust announced it will close and liquidate the Siren DIVCON Leaders Dividend ETF (LEAD) and Siren NexGen Economy ETF (BLCN) by July 21, 2026. Shareholders can sell or redeem shares until July 14, 2026, after which the funds will be managed for orderly liquidation. Liquidation proceeds may differ from current market value and will be taxable for investors in taxable accounts. Investors should consult tax advisors and expect potential tracking errors and changes in investment strategies during the wind-down period.

More News

Idaho Copper prices $18M public offering, plans NYSE American listing July 2, 2026

Idaho Copper prices $18M public offering, plans NYSE American listing July 2, 2026

Idaho Copper Corporation announced an $18 million public offering of common stock and warrants priced at $4.85 per share, with an additional 45-day option for over-allotments. The proceeds will fund an updated Preliminary Economic Assessment, initial...

Company Fundamentals
Bullish
1 hour ago
Global neonatal infant care market to reach $5.59B by 2035 with 6.21% CAGR driven by rising preterm births.

Global neonatal infant care market to reach $5.59B by 2035 with 6.21% CAGR driven by rising preterm births.

The global neonatal infant care market, valued at $3.06 billion in 2025, is projected to grow to $5.59 billion by 2035 at a CAGR of 6.21%. Growth is driven by increasing preterm births and neonatal complications like respiratory disorders and jaundic...

Market News
Neutral
2 hours ago
FDA approves Casgevy gene therapy for children 2+ with sickle cell disease and beta thalassemia

FDA approves Casgevy gene therapy for children 2+ with sickle cell disease and beta thalassemia

The FDA has approved Casgevy, a gene therapy using CRISPR technology, for children aged 2 and older with sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT). This therapy modifies patients' own stem cells to increase fetal hemo...

Market News
Neutral
3 hours ago
ClearBridge Energy Midstream Fund holds with 8.6% yield but faces risks from concentration and leverage.

ClearBridge Energy Midstream Fund holds with 8.6% yield but faces risks from concentration and leverage.

ClearBridge Energy Midstream Opportunity Fund (EMO) maintains a hold rating due to its attractive 8.6% monthly dividend yield, supported by earnings and tax-efficient distributions. However, the fund's concentrated exposure to a few midstream energy ...

Analyst Insights
Neutral
4 hours ago
FDA approves advancement of Telix's ProstACT Phase 3 trial for prostate cancer in the U.S.

FDA approves advancement of Telix's ProstACT Phase 3 trial for prostate cancer in the U.S.

Telix Pharmaceuticals received FDA agreement to advance Part 2 of its ProstACT Global Phase 3 trial for TLX591-Tx in metastatic castration resistant prostate cancer in the U.S. The FDA approved the clinical protocol, statistical plan, and safety data...

Company Fundamentals
Bullish
4 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App